PAMGENE PLATFORM ADOPTED FOR KINASE DRUG R&D PROGRAM: COLLABORATION WITH J&JPRD
PamGene International BV of 's-Hertogenbosch, The Netherlands, and Johnson &
Johnson Pharmaceutical Research & Development (J&JPRD), a division of
Janssen Pharmaceutica NV of Beerse, Belgium, have announced significant progress
in their kinase profiling collaboration. After extensive evaluation, PamGene's
microarray-based biochemical kinase activity profiling and cellular inhibition
assays will be further implemented in J&JPRD's research programs.